We are live on
!
Find out more
OAM
Oberweis Asset Management Portfolio holdings
AUM
$3.39B
1-Year Est. Return
105.5%
This Fund
S&P 500
This Quarter
Est. Return
+11.11%
1 Year Est. Return
+105.5%
3 Year Est. Return
+311.52%
5 Year Est. Return
+632.9%
10 Year Est. Return
+11,604.3%
AUM
$2.73B
AUM Growth
+$123M
(+4.7%)
Cap. Flow
+$6.55M
Cap. Flow
% of AUM
0.24%
Top 10 Holdings %
Top 10 Hldgs %
20.79%
Holding
204
New
21
Increased
104
Reduced
20
Closed
25
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Arcutis Biotherapeutics
ARQT
|
+$20.7M |
| 2 |
Globus Medical
GMED
|
+$20.5M |
| 3 |
Dana Inc
DAN
|
+$16.9M |
| 4 |
SGHC Ltd
SGHC
|
+$15.3M |
| 5 |
CNR
Core Natural Resources Inc
CNR
|
+$15.2M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
ADMA Biologics
ADMA
|
+$39.8M |
| 2 |
Sportradar
SRAD
|
+$37.1M |
| 3 |
Itron
ITRI
|
+$35.4M |
| 4 |
Stride
LRN
|
+$27.1M |
| 5 |
Qorvo
QRVO
|
+$23.8M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 37.24% |
| 2 | Healthcare | 19.19% |
| 3 | Industrials | 17.15% |
| 4 | Consumer Discretionary | 13.69% |
| 5 | Financials | 4.38% |
Similar funds
BG
DFO
VFCM
BCM
MCM
EFM
DIA
5NCM
Oberweis Asset Management's Q4 2025 Portfolio in Review
As of Q4 2025, Oberweis Asset Management held 204 positions worth $2.73B, up 4.7% from $2.61B the previous quarter. Its ten largest holdings account for 21% of the portfolio.
Oberweis Asset Management's Q4 2025 filing shows 21 new, 104 increased, 20 reduced and 25 closed positions. Its largest new stake was Arcutis Biotherapeutics: 808,400 shares worth $23.5M. The largest sale was ADMA Biologics, an estimated $39.8M.
By sector, the portfolio is most concentrated in Technology at 37% of assets, down from 41% a quarter earlier, followed by Healthcare and Industrials.
- Oberweis Asset Management's largest Q4 2025 buy was Arcutis Biotherapeutics: 808,400 shares worth $23.5M.
- Oberweis Asset Management added most to Alphatec Holdings in Q4 2025, an estimated $9.98M increase.
- Oberweis Asset Management's biggest Q4 2025 reduction was Lumentum, cutting an estimated $12.3M.
- Oberweis Asset Management fully exited ADMA Biologics in Q4 2025, selling an estimated $39.8M.
- Oberweis Asset Management's ten largest holdings make up 21% of its $2.73B portfolio in Q4 2025.
- Oberweis Asset Management opened 21 new positions and closed 25 in Q4 2025.
- Oberweis Asset Management's portfolio value rose 4.7% quarter-over-quarter to $2.73B.
Based on Oberweis Asset Management's 13F filing for Q4 2025, filed 17 Feb 2026.